Calliditas Therapeutics AB ADR (CALT): Price and Financial Metrics

Calliditas Therapeutics AB ADR (CALT): $23.56

0.06 (+0.26%)

POWR Rating

Component Grades













CALT Stock Price Chart Interactive Chart >

Price chart for CALT

CALT Price/Volume Stats

Current price $23.56 52-week high $25.49
Prev. close $23.50 52-week low $10.82
Day low $23.56 Volume 400
Day high $23.56 Avg. volume 14,453
50-day MA $20.06 Dividend yield N/A
200-day MA $17.81 Market Cap 701.76M

Calliditas Therapeutics AB ADR (CALT) Company Bio

Calliditas Therapeutics AB provides pharmaceutical products for patients with niche indications. It focuses on development and commercialization of the product candidate Nefecon intended for treatment of patients with the inflammatory renal disease IgA nephropathy. The company was founded by Mikael Bender and Bengt Åke Julander on February 20, 2004 and is headquartered in Stockholm, Sweden.

CALT Latest News Stream

Event/Time News Detail
Loading, please wait...

CALT Latest Social Stream

Loading social stream, please wait...

View Full CALT Social Stream

Latest CALT News From Around the Web

Below are the latest news stories about CALLIDITAS THERAPEUTICS AB that investors may wish to consider to help them evaluate CALT as an investment opportunity.

3 Supercharged Stocks Near 52-Week Highs That Could Keep Climbing

The main stock indexes are way down over the past year, but quite a few under-the-radar stocks have bucked the trend. Reata Pharmaceuticals (NASDAQ: RETA) was a clinical-stage biopharmaceutical company until the U.S. Food and Drug Administration (FDA) approved its first treatment on Feb. 28, 2023. Reata's first approved product, Skyclarys, is the first and only drug approved to treat Friedreich's ataxia, an ultra-rare neuromuscular disease.

Yahoo | March 19, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday!

William White on InvestorPlace | March 13, 2023

Calliditas Plans To File For Complete FDA Approval For Rare Kidney Disease Drug After Positive Phase 3 Data

Calliditas Therapeutics AB (NASDAQ: CALT) announced topline results from the Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon (TARPEYO/Kinpeygo (budesonide) delayed-release capsules) versus placebo in patients with primary IgA nephropathy (IgAN). The trial studied Nefecon on primary IgA nephropathy (IgAN) patients who were also on RAS inhibitor therapy. The drug demonstrated a "highly statistically significant benefit" over the placebo in two years, with nine months of t

Yahoo | March 13, 2023

Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy

Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced positive topline results from the global, randomized, double-blind, placebo-controlled Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon (TARPEYO®/Kinpeygo® (budesonide) delayed release capsules) versus placebo in patients with primary IgA nephropathy (IgAN).

Yahoo | March 13, 2023

Analyst Sits On Fence While Initiating Calliditas Citing 'Near-Term Opportunity But Longer-Term Questions'

Guggenheim initiated coverage on Calliditas Therapeutics AB (NASDAQ: CALT) with a Neutral rating and an $18 price target. The analyst is impressed with the data Tarpeyo has generated in Immunoglobulin A Nephropathy (IgAN) to date and the initial success the company has had with the commercial rollout of the product. While the analyst commends the Calliditas team for their progress with Tarpeyo in IgAN, including obtaining FDA Accelerated Approval and EU Conditional Approval, it notes mixed physi

Yahoo | March 1, 2023

Read More 'CALT' Stories Here

CALT Price Returns

1-mo 27.28%
3-mo 38.59%
6-mo 55.35%
1-year 18.57%
3-year N/A
5-year N/A
YTD 38.59%
2022 -31.34%
2021 -26.35%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6521 seconds.